Shares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance
1. Novo Nordisk cuts full-year sales and profit guidance. 2. Weaker growth expectations for Wegovy in the U.S. market. 3. Shares dropped 15% shortly after the announcement.
FAQ
Why Very Bearish?
A 15% drop indicates significant investor concern over revised sales forecasts. Historically, similar revisions lead to substantial share price declines.
How important is it?
The downgrade in guidance directly impacts investor confidence and future earnings estimates.
Why Short Term?
The immediate market reaction suggests investors will reassess NVO quickly. Previous profit guidance cuts typically result in rapid price adjustments.